LRMR
Larimar Therapeutics Inc
NASDAQ: LRMR · HEALTHCARE · BIOTECHNOLOGY
$4.06
-6.45% today
Updated 2026-04-30
Market cap
$461.24M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-2.27
Dividend yield
—
52W range
$2 – $6
Volume
5.0M
Larimar Therapeutics Inc (LRMR) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-12.27M | $-13.59M | $-15.00M | $-28.24M | $-59.55M | $-51.98M | $-43.78M | $-51.49M | $-22.70M | $-42.20M | $-42.10M | $-27.57M | $-33.46M | $-70.76M | $-113.20M |
| Capital expenditures | $35000.00 | $2000.00 | $17000.00 | $58000.00 | $595000.00 | $660000.00 | $55000.00 | $108000.00 | $83000.00 | $62000.00 | $333000.00 | $100000.00 | $163999.00 | $515000.00 | $91000.00 |
| Depreciation | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock-based comp | — | — | — | $1.55M | $8.58M | — | — | $173000.00 | $129000.00 | $2.16M | $5.47M | $6.62M | $7.62M | $8.80M | $7.00M |
| Free cash flow | $-12.31M | $-13.59M | $-15.02M | $-28.30M | $-60.15M | $-52.63M | $-43.84M | $-51.59M | $-22.78M | $-42.26M | $-42.44M | $-27.67M | $-33.62M | $-71.28M | $-113.29M |
| Investing cash flow | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | — | — | — | — | — | — | — | $68.48M | — | $-43.27M | — | — | — |